Literature DB >> 35818156

Essentials of allergen immunotherapy: A primer for the practitioner.

Joseph A Bellanti1, Russell A Settipane2, Lawrence DuBuske3.   

Abstract

It has been more than a decade since the most recent allergen immunotherapy (AIT) practice parameter was published and 5 years since a focused practice parameter on sublingual immunotherapy (SLIT) was issued. There is an unmet need, therefore, for a more up-to-date, concise summary of AIT to be published to provide allergy/immunology practitioners, allergy/immunology fellows-in-training, medical students, residents, and other health-care practitioners with the most current information available on AIT. The Allergen Immunotherapy Primer (AITP) is not intended to define a standard of care or to be inclusive of all proper methods of care, nor is it intended to replace or supplant established AIT practice parameters; rather, the goal of this AITP is to supplement the established practice parameters and to serve primarily as an updated tool for the practicing allergist/immunologist, allergy/immunology trainees, and health-care professionals seeking practical and concise information with regard to AIT. Primer topics include the history of AIT; descriptions of the mechanisms and biomarkers of subcutaneous immunotherapy (SCIT) and SLIT; the efficacy and safety of SCIT; the efficacy and safety of SLIT, pediatric SLIT, and SCIT; the long-term efficacy of SLIT and SCIT; long-term adherence strategies for AIT; the implications of real-world data for AIT; the role of AIT for asthma; patterns of cross-allergenicity among pollens; a practical implementation guide for optimized construction of AIT vaccines; standardization of allergen extracts; updated information on federal regulations about the United States Pharmacopeia and the compounding of allergenic extracts; an update on AIT venom immunotherapy; the advantages and disadvantages of accelerated immunotherapy regimens; the important role of shared decision-making in AIT and how it can be incorporated into the informed consent process; and a forecast of future directions in allergen immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35818156      PMCID: PMC9274934          DOI: 10.2500/aap.2022.43.220039

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.873


  5 in total

1.  Hereditary angioedema: an instructive model of clinical description, molecular discovery, and development of new effective treatments.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2011 Sep-Oct       Impact factor: 2.587

2.  Sublingual immunotherapy: A focused allergen immunotherapy practice parameter update.

Authors:  Matthew Greenhawt; John Oppenheimer; Michael Nelson; Hal Nelson; Richard Lockey; Phil Lieberman; Anna Nowak-Wegrzyn; Anju Peters; Charlotte Collins; David I Bernstein; Joann Blessing-Moore; David Khan; David Lang; Richard A Nicklas; Jay M Portnoy; Christopher R Randolph; Diane E Schuller; Sheldon L Spector; Stephen A Tilles; Dana Wallace
Journal:  Ann Allergy Asthma Immunol       Date:  2017-03       Impact factor: 6.347

3.  Northwestern University Allergy-Immunology Syllabus.

Authors:  Paul A Greenberger; Carol A Saltoun; Leslie C Grammer
Journal:  Allergy Asthma Proc       Date:  2019-11-01       Impact factor: 2.587

Review 4.  Allergen immunotherapy practice in the United States: guidelines, measures, and outcomes.

Authors:  Linda Cox; Robert E Esch; Mark Corbett; Cheryl Hankin; Michael Nelson; Greg Plunkett
Journal:  Ann Allergy Asthma Immunol       Date:  2011-07-31       Impact factor: 6.347

5.  The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses.

Authors:  Mohamed H Shamji; Louisa K Wilcock; Petra A Wachholz; Rebecca J Dearman; Ian Kimber; Peter A Wurtzen; Mark Larché; Stephen R Durham; James N Francis
Journal:  J Immunol Methods       Date:  2006-10-05       Impact factor: 2.303

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.